Aclarion's Nociscan Wins Pinnacle Award for AI in Clinical Decisions — Aclarion, Inc.

Event summary

Aclarion received the Diamond Pinnacle Award for AI Innovation in Clinical Decision AI on April 14, 2026.
The award recognizes Aclarion’s Nociscan solution for chronic low back pain, following its 2025 HLTH Digital Health Award.
Nociscan uses MR spectroscopy and AI to identify painful discs, with a 97% surgical success rate when all Nociscan-positive discs are treated.
The company’s cloud-based platform allows rapid deployment across imaging centers without new hardware infrastructure.

The big picture

Aclarion’s recognition underscores the growing validation of AI-driven diagnostic tools in healthcare, particularly for chronic conditions like low back pain. The awards highlight the potential for Nociscan to transform clinical decision-making by providing objective biochemical data, addressing a significant unmet need in the $266 million global market for degenerative spine disease. The company’s cloud-based model positions it for rapid scalability, but its success will depend on sustained adoption and clinical outcomes.

What we're watching

Adoption Pace: How quickly Aclarion can expand Nociscan adoption among spine specialists and health systems.
Market Validation: Whether the Pinnacle and HLTH awards will translate into increased investor confidence and market traction.
Technological Scalability: The pace at which Aclarion can scale its cloud-based analytics platform to handle broader clinical applications.